Akero Therapeutics, Inc. Long-Term Debt, Maturity, Year Four
Akero Therapeutics, Inc. had Long-Term Debt, Maturity, Year Four of $7.22 million as of 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour · last filed 2025-02-28
- 2024-12-31: Long-Term Debt, Maturity, Year Four $7.22M.
- 2023-12-31: Long-Term Debt, Maturity, Year Four $1.54M; Long-Term Debt, Maturity, Year Four as first filed $16.12M.
- 2023-09-30: Long-Term Debt, Maturity, Year Four $1.01M.
- 2023-06-30: Long-Term Debt, Maturity, Year Four $1.00M.
| Period end | Long-Term Debt, Maturity, Year Four | Long-Term Debt, Maturity, Year Four as first filed |
|---|---|---|
| 2024-12-31 | $7.22M 10-K · filed 2025-02-28 | |
| 2023-12-31 | $1.54M 10-K · filed 2025-02-28 | $16.12M 10-K · filed 2024-02-29 |
| 2023-09-30 | $1.01M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $1.00M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $1.00M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $4.17M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $4.14M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $4.10M 10-Q · filed 2022-08-05 |